Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Dermatology

Emerging Frontiers: Biologics and New Therapies

At a Glance

Emerging treatments for inherited ichthyosis use biologics and JAK inhibitors to target the underlying immune response. Though often prescribed off-label, these precision therapies offer hope for significantly reducing severe skin scaling, redness, and itching by addressing root-cause inflammation.

For decades, treating ichthyosis was limited to external “management”—scrubbing and moisturizing. Today, we are entering a new era of precision medicine [1]. Scientists have discovered that while ichthyosis starts with a genetic “typo” in the skin barrier, the body’s immune system often overreacts to that leak, creating a cycle of chronic inflammation [1][2]. New treatments, called biologics and targeted therapies, aim to turn down that internal “volume” [1][3].

The Th17/IL-23 “Fingerprint”

Many forms of ichthyosis (including ARCI and Epidermolytic types) share an immune profile with psoriasis called the Th17/IL-23 pathway [1][2]. In these patients, the body produces too much of a protein called IL-17, which tells the skin to grow even faster and become red and inflamed [1][4].

IL-17 Inhibitors (e.g., Secukinumab, Ixekizumab)

These injectable medications selectively block the IL-17 protein [5].

  • The Hope: Case studies have shown remarkable results for some children, with significant clearing of redness and scaling [6][7].
  • The Reality: A large clinical trial recently showed that these drugs don’t work for everyone with ichthyosis [8]. They seem to be most effective for patients who have very high levels of skin inflammation [8].

Targeted Options for Netherton Syndrome

Netherton syndrome often behaves differently than other types, appearing more like severe eczema or an “allergic” skin reaction (the Th2 pathway) [9][10].

  • Dupilumab: This biologic targets the Th2 pathway [9]. In several small studies, it has significantly reduced the intense itching and “eczema-like” rashes common in Netherton syndrome [9][10][11].
  • JAK Inhibitors (e.g., Abrocitinib, Upadacitinib): These are oral medications that block multiple inflammatory signals at once [12]. They are emerging as a powerful “rescue” therapy for Netherton syndrome, providing rapid relief from severe skin symptoms [13].

Hope through Clinical Trials and “Off-Label” Use

Most of these new drugs are already FDA-approved for other conditions, like psoriasis or atopic dermatitis, but not specifically for ichthyosis [14][15]. When a doctor prescribes them for ichthyosis, it is called “off-label” use [16].

  • Clinical Trials: These are research studies where patients can access new treatments under close supervision [17]. This is the primary way we learn which drugs work best for which genetic types of ichthyosis.
  • Experimental Nature: While these treatments offer a hopeful future, they are still considered experimental for ichthyosis [8]. Long-term safety in children with rare skin diseases is still being studied, and common risks include an increased chance of certain infections [18][19].

This is a fast-moving field. What was impossible five years ago is now being tested in clinics around the world, bringing us closer to treatments that address the root cause of the inflammation [1][20].

Common questions in this guide

What are biologic treatments for inherited ichthyosis?
Biologics are precision medications that target specific parts of the body's overactive immune system. Instead of just moisturizing the surface of the skin, they help block the internal inflammation that causes excessive skin growth, redness, and scaling.
Will IL-17 inhibitors work for my child's ichthyosis?
IL-17 inhibitors can significantly clear redness and scaling for some children, but they do not work for everyone. Studies show they are most effective for patients who have very high levels of skin inflammation driven by the Th17 immune pathway.
What new treatments are available specifically for Netherton syndrome?
Netherton syndrome often behaves like severe eczema and responds to drugs targeting the Th2 immune pathway. Medications like dupilumab and oral JAK inhibitors are emerging as powerful rescue therapies to provide rapid relief from intense itching and rashes.
What does it mean if a medication is prescribed 'off-label'?
Off-label use means a doctor prescribes a medication that is officially approved for another condition, like psoriasis or eczema, to treat your ichthyosis. This is very common with new biologics because they are not yet FDA-approved specifically for rare skin disorders like ichthyosis.
How do we find out if these new therapies are right for us?
Your dermatologist can evaluate if your specific type of ichthyosis matches the immune 'fingerprints' these new drugs target. You can also ask your doctor about current clinical trials, which offer a way to access experimental treatments under close medical supervision.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my child’s specific type of ichthyosis show the 'Th17' or 'Th2' immune fingerprint that these new drugs target?
  2. 2.Are there any current clinical trials for biologics or JAK inhibitors that my child might be eligible for?
  3. 3.What are the risks of using these medications 'off-label' in a child, and how would we monitor for side effects like infections or bowel issues?
  4. 4.If my child has severe allergies and itching, would a Th2 inhibitor like dupilumab be a better option than an IL-17 inhibitor?
  5. 5.How long should we try a new biologic before deciding if it is working for my child’s skin?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis.

    Paller AS, Renert-Yuval Y, Suprun M, et al.

    The Journal of allergy and clinical immunology 2017; (139(1)):152-165 doi:10.1016/j.jaci.2016.07.019.

    PMID: 27554821
  2. 2

    Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses.

    Paller AS

    The Journal of investigative dermatology 2019; (139(3)):535-540 doi:10.1016/j.jid.2018.08.027.

    PMID: 30670307
  3. 3

    Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection.

    Megna M, Patruno C, Bongiorno MR, et al.

    The Journal of dermatological treatment 2022; (33(5)):2629-2633 doi:10.1080/09546634.2022.2062280.

    PMID: 35385362
  4. 4

    The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood.

    Czarnowicki T, He H, Leonard A, et al.

    The Journal of investigative dermatology 2018; (138(10)):2157-2167 doi:10.1016/j.jid.2018.03.1523.

    PMID: 29660300
  5. 5

    Secukinumab: A Review in Psoriatic Arthritis.

    Shirley M, Scott LJ

    Drugs 2016; (76(11)):1135-45 doi:10.1007/s40265-016-0602-3.

    PMID: 27299434
  6. 6

    Case report: Interleukin-17 targeted biological therapy in netherton syndrome.

    Mahajan R, Bakshi S, Kumar A, et al.

    Frontiers in pediatrics 2023; (11()):1297658 doi:10.3389/fped.2023.1297658.

    PMID: 38094185
  7. 7

    First successful treatment of epidermolytic Ichthyosis with Vunakizumab: A Case Report.

    Cheng W, Pan C, Sun Z, et al.

    Frontiers in immunology 2025; (16()):1574255 doi:10.3389/fimmu.2025.1574255.

    PMID: 40453098
  8. 8

    Secukinumab responses vary across the spectrum of congenital ichthyosis in adults.

    Lefferdink R, Rangel SM, Chima M, et al.

    Archives of dermatological research 2023; (315(2)):305-315 doi:10.1007/s00403-022-02325-3.

    PMID: 35218370
  9. 9

    Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation.

    Yan S, Wu X, Jiang J, et al.

    Frontiers in immunology 2022; (13()):1054422 doi:10.3389/fimmu.2022.1054422.

    PMID: 36569942
  10. 10

    Response to dupilumab in two children with Netherton syndrome: Improvement of pruritus and scaling.

    Süßmuth K, Traupe H, Loser K, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(2)):e152-e155 doi:10.1111/jdv.16883.

    PMID: 32810299
  11. 11

    Netherton syndrome: effect on ichthyosis linearis circumflexa with dupilumab.

    Chu AKY, Cheng JWC, Lam YY, et al.

    The Journal of dermatological treatment 2025; (36(1)):2576575 doi:10.1080/09546634.2025.2576575.

    PMID: 41128136
  12. 12

    JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases.

    Melki I, Frémond ML

    Journal of clinical medicine 2023; (12(14)) doi:10.3390/jcm12144695.

    PMID: 37510809
  13. 13

    Abrocitinib for Head and Neck Dermatitis: Case Series and Literature Review.

    Liu C, Pan Y, Xiong J, et al.

    Clinical, cosmetic and investigational dermatology 2025; (18()):3093-3102 doi:10.2147/CCID.S549045.

    PMID: 41293323
  14. 14

    Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.

    Gerdes S, Pinter A, Papavassilis C, Reinhardt M

    Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(3)):533-541 doi:10.1111/jdv.16004.

    PMID: 31599476
  15. 15

    Clinical updates of JAK inhibitors in cutaneous granulomatous diseases.

    Gu J, He X, Lu B, et al.

    Frontiers in immunology 2025; (16()):1698816 doi:10.3389/fimmu.2025.1698816.

    PMID: 41459541
  16. 16

    Dupilumab in Inflammatory Skin Diseases: A Systematic Review.

    Olbrich H, Sadik CD, Ludwig RJ, et al.

    Biomolecules 2023; (13(4)) doi:10.3390/biom13040634.

    PMID: 37189381
  17. 17

    Novel mixed-method, inclusive protocol involving global key stakeholders, including carers as experts, to co-develop relevant Caregiver-Reported Outcome Domains (CRODs) in skin disease.

    Walsh C, Leavey G, Mc Laughlin M, et al.

    BMJ open 2023; (13(1)):e068893 doi:10.1136/bmjopen-2022-068893.

    PMID: 36657764
  18. 18

    A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.

    Magnolo N, Kingo K, Laquer V, et al.

    Journal of the American Academy of Dermatology 2022; (86(1)):122-130 doi:10.1016/j.jaad.2021.08.066.

    PMID: 34555481
  19. 19

    Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study.

    Alsakarneh S, Al Ta'ani O, Aburumman R, et al.

    Alimentary pharmacology & therapeutics 2025; (62(1)):72-76 doi:10.1111/apt.70139.

    PMID: 40192577
  20. 20

    Rare diseases: challenges and opportunities for research and public health.

    Taruscio D, Gahl WA

    Nature reviews. Disease primers 2024; (10(1)):13 doi:10.1038/s41572-024-00505-1.

    PMID: 38424095

This information about emerging biologics and targeted therapies for inherited ichthyosis is for educational purposes only. Always consult a pediatric dermatologist or specialist before considering off-label treatments or clinical trials.

Get notified when new evidence is published on Inherited ichthyosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.